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Pulsatile Portal Vein Insulin Delivery Enhances Hepatic
Insulin Action and Signaling
Aleksey V. Matveyenko,1 David Liuwantara,1 Tatyana Gurlo,1 David Kirakossian,1
Chiara Dalla Man,2 Claudio Cobelli,2 Morris F. White,3 Kyle D. Copps,3 Elena Volpi,4
Satoshi Fujita,4 and Peter C. Butler1
Insulin is secreted as discrete insulin secretory bursts at ;5-min
intervals into the hepatic portal vein, these pulses being attenu-
ated early in the development of type 1 and type 2 diabetes mel-
litus (T2DM). Intraportal insulin infusions (pulsatile, constant, or
reproducing that in T2DM) indicated that the pattern of pulsatile
insulin secretion delivered via the portal vein is important for
hepatic insulin action and, therefore, presumably for hepatic in-
sulin signaling. To test this, we examined hepatic insulin signaling
in rat livers exposed to the same three patterns of portal vein
insulin delivery by use of sequential liver biopsies in anesthetized
rats. Intraportal delivery of insulin in a constant versus pulsatile
pattern led to delayed and impaired activation of hepatic insulin
receptor substrate (IRS)-1 and IRS-2 signaling, impaired activa-
tion of downstream insulin signaling effector molecules AKT and
Foxo1, and decreased expression of glucokinase (Gck). We fur-
ther established that hepatic Gck expression is decreased in the
HIP rat model of T2DM, a defect that correlated with a progres-
sive defect of pulsatile insulin secretion. We conclude that the
physiological pulsatile pattern of insulin delivery is important in
hepatic insulin signaling and glycemic control. Hepatic insulin
resistance in diabetes is likely in part due to impaired pulsatile
insulin secretion. Diabetes 61:2269–2279, 2012
Fasting hyperglycemia in both type 1 and type 2diabetes mellitus (T1DM and T2DM, respectively)is due to increased hepatic glucose release asa result of insufficient insulin secretion in the
context of relative hepatic insulin resistance (1,2). Defective
insulin secretion and insulin resistance both develop early
in the evolution of T1DM and T2DM (3–5). Hepatic insulin
resistance coincides with impaired insulin secretion and
precedes diabetes onset in animal models of T2DM with
progressive b-cell loss (6,7). Likewise, hepatic insulin re-
sistance develops with b-cell loss in animal models of T1DM
(8,9). This raises the question, does b-cell failure contribute
to hepatic insulin resistance?
Insulin is secreted in coordinate secretory bursts into
the hepatic portal vein with a periodicity of ;5 min (10,11).
Insulin secretion is regulated by the magnitude of insulin
pulses (12,13). Thus, hepatocytes are exposed to an oscil-
lating insulin concentration wave front with an amplitude of
;0.5–1.0 nmol/L in the fasting state and increasing to ;5.0
nmol/L after meal ingestion (11,12). The vascular anatomy
of hepatic sinusoids permits direct exposure of hepatocytes
to these insulin oscillations.
Since pulsatile insulin delivery in T1DM and T2DM is
impaired (14–16), defective pulsatile insulin delivery may
contribute to diminished hepatic insulin signaling and he-
patic insulin resistance in diabetes. While several studies
have approached this question (11,17–21), none have de-
livered insulin into the portal vein to reproduce the insulin
concentration oscillations and timing present in vivo. To
address this, we developed an intraportal infusion protocol
in conscious dogs that reproduced the in vivo pulsatile
insulin concentration profile in the fasting state (10,11).
We then compared this with the same insulin infusion rate
delivered as a constant infusion and with an insulin in-
fusion profile that recapitulated defective pulsatile insulin
secretion present in T2DM (15). We established first in the
dog and then confirmed in the rat that physiological insulin
pulses delivered into the portal vein enhance insulin ac-
tion. We then tested the hypothesis that the mechanism of
this was greater efficacy of the pulsatile mode of insulin
delivery on hepatic insulin signaling and gene expression.
RESEARCH DESIGN AND METHODS
Canine studies
Study protocol. The institutional animal care and use committee at the
University of California Los Angeles approved all dog studies. Five mongrel
dogs aged ;1–3 years and weighing 20–24 kg were used in the current studies.
Animal care and catheter implantation were performed as previously de-
scribed (10). Dogs were studied on three separate occasions after a 12-h fast.
On each occasion, dogs were placed in a laboratory sling and endogenous
insulin secretion was ablated by a 0.8 µg $ kg21 $ min21 somatostatin infusion
(somatostatin-14; Bachem, Torrance, CA) with basal replacement of glucagon
at 0.65 ng $ kg21 $min21 (Glucagen; Bedford Laboratories, Bedford, OH) given
via foreleg infusion catheter throughout the study (0–300 min). A primed
continuous infusion of [6,6-2H2]glucose was given at a rate of 3 mg/kg/h to
trace glucose turnover. The insulin infusion rate required to maintain fasting
glucose concentrations in each dog when insulin was delivered via the portal
vein in the normal pulsatile fashion was determined for each dog in a pilot
study prior to the three study protocols.
For protocol 1 (pulsatile insulin delivery), insulin was infused at the rate
previously established in each dog (range 0.9–2.0, mean 1.2 pmol $ kg21 $min21)
with 70% as 1-min pulses at 6-min intervals and 30% as a constant basal insulin
infusion from 0 to 300 min. For protocol 2 (constant insulin delivery), the same
total insulin infusion rate for each dog was administered but 100% as a constant
infusion. For protocol 3 (T2DM pulsatile infusion), insulin infusion was com-
parable with protocol 1 except that the magnitude of the insulin pulses was
decreased by 50%, reproducing the pattern present in T2DM (15). The mean
insulin infusion rate for the T2DM protocol equaled 0.81 pmol $ kg21 $ min21
(0–300 min). Blood was sampled at 10- to 30-min intervals (0–300 min) from the
foreleg venous catheter for measurement of glucose, insulin, C-peptide, and
glucagon concentrations. Blood was sampled at 1-min intervals from the portal
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vein catheter for 40 min (140–180 min) for measurement of insulin concen-
trations to permit evaluation of the efficacy of the three mesenteric vein insulin
infusion profiles in accomplishing the desired portal vein insulin profiles (Sup-
plementary Fig. 1).
Rat studies. More detailed methods for the rat studies are provided in the
Supplementary Data online. The institutional animal care and use committee
at the University of California Los Angeles approved all rat studies. A total of
71 Sprague-Dawley male rats aged 5 months had catheters placed as described
(22). The efficacy of pulsatile insulin delivery on glycemia (protocol 1), insulin
sensitivity (protocol 2), and hepatic insulin signaling (protocols 3–5) were
then evaluated as follows. In protocol 1, conscious rats were studied, in
a manner comparable with that undertaken in dogs, by ablation of endogenous
insulin secretion with somatostatin and replacement of basal glucagon (0.65
ng $ kg21 $ min21) and insulin (5 pmol $ kg21 $ min21) to reproduce fasting
secretion rates in the rats with the three profiles (pulsatile, constant, and
T2DM) used in dogs. In protocol 2, a second cohort of conscious rats were
studied during a modified hyperinsulinemic euglycemic clamp during sup-
pression of endogenous insulin secretion with insulin infused intraportally in
the same three patterns as before but at a rate to mimic the postprandial state
in the rats (70 pmol $ kg21 $ min21). Third, to establish the efficacy of the
same three patterns of insulin delivery on hepatic insulin signaling, anes-
thetized rats received the same three intraportal insulin infusions during
suppression of endogenous insulin secretion for 10 min (protocol 3) or 30 min
(protocol 4), with sequential liver biopsies obtained to measure insulin
signaling, blood glucose being clamped. To overcome potential confounding
effects of varying portal insulin concentrations on immediate insulin signaling,
we repeated protocol 4 but after 120 min, increased the intraportal insulin
infusion to a comparable constant high rate for 30 min before liver biopsy.
Thus, the effect of antecedent pulsatile versus constant insulin delivery on
insulin signaling in response to an identical increment in insulin concentration
was evaluated (protocol 5). Finally, to extend the findings of the relatively
short-term intraportal vein insulin infusions possible to a longer-term setting,
we studied the HIP rat model of T2DM (n = 39) and age-matched Sprague
Dawley controls (n = 36) at aged 2, 7, and 12 months. Intraportal vein insulin
sampling and quantification of pulsatile insulin secretion undertaken as
previously described (22) affirmed a progressive defect in pulsatile insulin
secretion in the HIP rat. This model therefore permitted concurrent evalu-
ation of hepatic glucokinase (Gck) gene expression, the major downstream
insulin signaling target noted to be impaired with abnormal insulin delivery,
in HIP and wild-type rats at aged 2, 7, and 12 months.
Glucose kinetics. Blood glucose enrichment was measured by gas chroma-
tography mass spectrometry after extraction by ion exchange chromatography
and derivatization to penta-acetate.
Immunoprecipitation and immunoblotting analysis. Tissue lysates were
prepared from frozen liver samples and homogenized in standard lysis buffer
A supplemented with the protease inhibitor cocktail (Roche, Mannheim,
Germany). For immunoprecipitation of insulin receptor substrate (IRS)-1,
IRS-2, and forkhead box class o (Foxo)1, 1 mg liver extracts were incubated
with rabbit polyclonal antibodies against IRS-1, IRS-2, and Foxo1 overnight at
4°C. Protein A-agarose (Millipore, Temecula, CA) then was added and in-
cubated for 2 h at 4°C. Immunocomplexes were resolved on 8% Bis-Tris
n-PAGE (Invitrogen). Phosphorylated or total protein was analyzed by im-
munoblotting with specific antibodies against IRS-1 (06–248), IRS-2, (06–506),
p85 (06–195), and p-tyrosine (05–321) purchased from Millipore and anti-
bodies specific for AKT (9272), AKT (Ser473) (9271), Foxo1 (2880), and Foxo1
(Ser256) (9461) purchased from Cell Signaling. Protein signals were detected
with horseradish peroxidase–conjugated secondary antibodies (Invitrogen)
using an enhanced chemiluminescence detection system. Images were ana-
lyzed and quantified using LabWorks Image Acquisition and Analysis software
(UVP, Upland, CA).
Immunofluorescence. Liver tissue was fixed in 4% paraformaldehyde for
24 h at 4°C and embedded in paraffin. Sections (4 mm) were stained for
Foxo1 (1:25 dilution) and glutamine synthase (1:100; BD Transduction
Laboratories, San Jose, CA). Secondary antibodies labeled with Cy3 and
fluorescein isothiocyanate were obtained from Jackson ImmunoResearch
Laboratories (West Grove, PA) and used at dilutions of 1:100 for 1-h in-
cubation. Slides were viewed using a Leica DM6000 microscope (Leica
Microsystems, Bannockburn, IL), and images were acquired using OpenLab
software (Improvision, Lexington, MA).
Real-time PCR. Total RNA was isolated with the RNeasy kit (QIAGEN), and
cDNA synthesis was performed using the SuperScript III First-Strand synthesis
kit (Invitrogen) according to manufacturers’ instructions. The real-time PCR
was carried out with the LightCycler FastStart DNA MasterPLUS SYBR Green I
(Roche) using gene-specific primers following manufacturer’s instructions.
Analytical procedures. Plasma glucose concentrations were measured using
Beckman Glucose Analyzer. Insulin, C-peptide, and glucagon were measured in
canine plasma samples by radioimmunoassay (LincoResearch Inc., St. Louis, MO).
Rat insulin was measured using an ELISA (ALPCO Diagnostics, Salem, NH).
Plasma free fatty acid levels were measured using the colorimetric method
(WAKO Chemicals, Richmond, VA).
Calculations. Insulin secretion rates were calculated as previously described
in detail (10,22). The rates of hepatic glucose release during the last 60 min of
the insulin replacement period were calculated by use of steady-state equa-
tions, the percent enrichment being confirmed to be at steady state (Supple-
mentary Fig. 2).
Statistical analysis. Statistical analysis was performed using the ANOVA
analysis, with Fisher post hoc when appropriate (Statsoft, Tulsa, OK). Signifi-
cance was assigned at P , 0.05.
RESULTS
Effects of pulsatile insulin delivery on fasting glucose
concentration and insulin sensitivity. To establish if
the pattern of insulin concentration wave front presented
to the liver in health is important for regulation of blood
glucose and insulin sensitivity, first we studied dogs on
three occasions with three different intraportal insulin in-
fusion protocols. Concurrent portal vein sampling assured
that the appropriate portal vein insulin concentration
profiles were accomplished (Supplementary Fig. 1). With
intraportal physiological pulsatile insulin delivery, the
plasma glucose concentration decreased slightly as ex-
pected with continued fasting (856 3 mg/dL after 300 min)
(Fig. 1C and D). In contrast, when the same rate of insulin
was infused in a constant manner, the plasma glucose
concentration increased to the impaired fasting glucose
concentration range (104 6 3 mg/dL after 300 min, P ,
0.05 vs. pulsatile) (Fig. 1C and D). Moreover, when intra-
portal insulin delivery was infused to reproduce the at-
tenuated pulses, and therefore decreased delivery rate
present in T2DM (15), the plasma glucose concentration
increased to values that would be adjudged as indicating
diabetes (137 6 11 mg/dL after 300 min, P , 0.05 vs.
pulsatile) (Fig. 1C and D). Hepatic glucose release sup-
pressed less despite higher blood glucose concentrations
in both T2DM and constant insulin infusions compared
with pulsatile insulin delivery (Fig. 1E). The insulin and
glucagon concentrations in the systemic circulation were
comparable in all three protocols throughout the study
period (P = NS) (Fig. 1F and G). As expected, the endog-
enous plasma C-peptide concentrations decreased to the
limits of detection during the somatostatin infusion during
all three intraportal delivery protocols (P = NS) (Fig. 1H).
Next, we performed a study, comparable with that
undertaken in dogs, in conscious rats with chronically
implanted mesenteric vein catheters delivering the same
pattern of three portal vein insulin infusions (Supplemen-
tary Fig. 3). As expected, the same pattern of blood glu-
cose values in rats arose so that after 240 min of the
pulsatile, constant, and T2DM pattern of intraportal insulin
infusion, values were 88 6 8 vs. 1136 6 vs. 160 6 3 mg/dL,
respectively (P , 0.05 vs. pulsatile) (Supplementary Fig. 3).
These data imply that the pattern of insulin delivery into
the portal vein influences insulin efficacy and signaling. To
confirm this, we performed a modified hyperinsulinemic-
euglycemic clamp in which insulin was infused via a mes-
enteric vein at a high physiological rate in the pulsatile,
constant, or T2DM pattern while blood glucose values were
clamped at euglycemia by a variable-rate glucose infusion
(Supplementary Fig. 4). Insulin efficacy, assessed by the mean
glucose infusion rate during this modified hyperinsulinemic-
euglycemic clamp, was decreased with constant or T2DM
insulin delivery compared with pulsatile (17 6 2 and 11 6 1
vs. 26 6 2 mg/kg/min; P , 0.05 vs. pulsatile) (Supplementary
Fig. 4).
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Effects of pulsatile insulin delivery on hepatic insulin
signaling. Having established that the intraportal pulsatile
insulin concentration wave front present in health is more
efficacious at regulating blood glucose than an equivalent
constant infusion rate or the pattern of insulin delivery in
T2DM, we next extended these findings to establish how
these patterns of portal insulin delivery differ in their
actions on the hepatic insulin signaling cascade. To ad-
dress this, we established an anesthetized rat model with
access to the liver for sequential liver biopsies. To evaluate
the impact of the different patterns of portal vein insulin
delivery on the proximal insulin signaling molecules, we
undertook studies with four consecutive liver biopsy sam-
ples obtained during the first 10 min of portal vein insulin
FIG. 1. Intraportal fasting insulin replacement protocol in dogs. A: All dogs had a portal vein sampling and mesenteric vein infusion catheter placed
surgically under general anesthesia. After a 5-day recovery period, each dog was exposed in random order to 1) pulsatile portal vein insulin in-
fusion, 2) constant portal vein insulin infusion, and 3) portal vein insulin infusion designed to reproduce that observed in patients with T2DM.
B: For each of these protocols, dogs were placed in a laboratory sling and somatostatin (0.8 µg/kg/min) and glucagon (0.65 ng/kg/min) were infused
through the foreleg catheter throughout the study (0–300 min). A primed (3 mg/kg) continuous (3 mg/kg/h) infusion of [6, 6-2H2]glucose was given
via foreleg catheter throughout the study to permit glucose turnover measurements. For the pulsatile protocol, insulin was infused into the
mesenteric vein catheter with 70% of insulin delivered in pulses and 30% as a basal constant insulin infusion. For constant insulin infusion,
the same total amount of insulin was delivered at a constant rate. For the T2DM protocol, insulin was delivered with 50% diminished pulses at the
same frequency and with same basal insulin delivery. C: Plasma glucose levels at baseline (230 to 0 min) and during intraportal insulin re-
placement (0–300 min). Mean plasma glucose (D) and hepatic glucose production (E) during the steady-state intraportal insulin replacement
period (260–300 min) after normal pulsatile (dark bar), constant (open bar), or T2DM (gray bar) intraportal insulin delivery in dogs. Systemic
plasma levels of insulin (F), glucagon (G), and C-peptide (H) at baseline (230 to 0 min) and during the intraportal insulin replacement study
period (0–300 min). Data are mean 6 SE. *P < 0.05 vs. pulsatile, **P < 0.05 vs. constant and pulsatile.
A.V. MATVEYENKO AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 61, SEPTEMBER 2012 2271
infusion protocols (Figs. 2–4). To evaluate the impact of
the different portal vein insulin profiles with an emphasis
on the more distal insulin signaling molecules over a time
frame consistent with putative varying actions of these
molecules on glucose homeostasis (vide supra), we eval-
uated hepatic insulin signaling after 30 min of intraportal
insulin delivery (Figs. 5 and 6).
For the 10-min sampling protocol (Fig. 2A and B), there
were no differences in plasma glucose or free fatty acid
concentrations between the three experimental protocols
during the 10 min of the study (Fig. 2D and E). Intraportal
delivery of insulin in a physiological pulsatile pattern ac-
complished acute and robust activation of both hepatic
IRS-1 and IRS-2 signaling with increased phosphorylation
of IRS-1– and IRS-2–associated phosphotyrosine (pY) and
p85 subunit of phosphatidylinositol (PI) 3-kinase (Fig. 3).
Activation of hepatic insulin signaling was delayed and
impaired when insulin was delivered at the same rate in a
constant manner with an ;50–80% reduction in both IRS-1
and IRS-2–associated pY and p85 subunit of PI 3-kinase
(P , 0.05 vs. pulsatile) (Fig. 3). When the intraportal
insulin delivery rate mimicked that in T2DM, IRS-1– and
IRS-2–associated pY and p85 subunit of PI 3-kinase ex-
pression were impaired to a similar extent as that seen
with the constant insulin infusion (Fig. 3). The delayed and
impaired activation of IRS-1 and IRS-2 with constant or
T2DM insulin pulses compared with physiological pulses
was mirrored by a comparable defect in activation of the
downstream insulin signaling effector molecules, such as
AKT and Foxo1 (Fig. 4). Specifically, insulin-stimulated
phosphorylation of AKT (at Ser473 residue) and Foxo1 (at
Ser256 residue) was diminished ;50–80% (P , 0.05 vs.
pulsatile) (Fig. 4) after constant or T2DM intraportal in-
sulin delivery compared with typical pulsatile pattern.
To better recapitulate in vivo conditions, we next exam-
ined effects of more prolonged (30 min) exposure to intra-
portal insulin delivery (Figs. 5 and 6) on hepatic insulin
signaling and gene expression, particularly focusing on
FIG. 2. Intraportal 10-min insulin delivery protocol in rats (rat protocol 3). A and B: Schematic representation of portal vein insulin infusion
procedure in rats. Rats were anesthetized and indwelling catheters were placed into the mesenteric vein, jugular vein, and carotid artery. Rats
received a constant intravenous infusion of somatostatin (10 mg/kg/min) for 30 min to inhibit endogenous insulin release. Insulin was infused
intraportally at the rate of 70 pmol/kg/min either in a typical pulsatile pattern, in a same-rate constant insulin infusion, or as an insulin infusion
selected to reproduce that observed in patients with evolving diabetes (;50% decrease in pulse mass). Sequential hepatic biopsies were obtained
at 0, 2, 6, and 10 min after the start of insulin infusion. Body weight (C), plasma glucose (D), and free fatty acid (E) levels were not significantly
different after the three modes of insulin delivery. Data are mean 6 SE.
INSULIN SECRETION AND HEPATIC INSULIN RESISTANCE
2272 DIABETES, VOL. 61, SEPTEMBER 2012 diabetes.diabetesjournals.org
activation of downstream insulin signaling targets AKT
and Foxo as well as a key glucoregulatory gene, Gck. By
design, the plasma glucose was clamped (Fig. 5C), and
free fatty acid concentrations did not differ between
groups during the 30-min observation period (Fig. 5D).
The glucose infusion rate required to maintain euglyce-
mia during the clamp was 50–70% decreased with the
constant or T2DM intraportal insulin delivery (P , 0.05
vs. pulsatile) (Fig. 5E) compared with the physiological
pulsatile infusion consistent with the studies in conscious
dogs and rats. In addition, insulin-stimulated phosphory-
lation of AKT at Ser473 residue (P , 0.05 vs. pulsatile)
and Foxo1 at Ser256 residue (P = 0.09 vs. pulsatile) were
diminished ;50% after constant or T2DM intraportal in-
sulin delivery compared with the normal pulsatile insulin
delivery (Fig. 6A and B). Consistent with the impaired
Foxo1 phosphorylation accomplished with either the
constant or T2DM pattern of insulin delivery, Foxo1 nu-
clear exclusion was also decreased compared with that
following the physiological pulsatile pattern of intraportal
insulin delivery (Fig. 6C).
We used real-time PCR to establish whether changes in
the pattern of hepatic insulin delivery influenced hepatic
gene expression of genes that regulate glucose homeo-
stasis. In particular, we focused on Gck since 1) it plays a
key role in regulating hepatic glucose fluxes (25), 2) its
FIG. 3. IRS-1 and IRS-2 activation after pulsatile, constant, or T2DM intraportal 10-min insulin delivery protocol in rats. Immunoblot (IB) analysis
of liver samples biopsied from rats exposed to 10 min of intraportal insulin delivered in either typical pulsatile fashion, same-rate constant in-
fusion, or reduced pulses (T2DM). Hepatic biopsies were obtained at 0, 2, 6, and 10 min consecutively from the same liver after the start of portal
vein insulin infusion. Activation of IRS-1 was examined by immunoprecipitation (IP) with an antibody against IRS-1, and the samples were then
immunoblotted with antibodies against pY (A and B) or p85 subunit of PI 3-kinase (C and D). Activation of IRS-2 was examined by immuno-
precipitation with an antibody against IRS-2, and the samples were then immunoblotted with antibodies against pY (E and F) or p85 subunit of PI
3-kinase (G and H). Data are mean 6 SE. *P < 0.05 vs. pulsatile.
A.V. MATVEYENKO AND ASSOCIATES
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activity is reduced in the liver in T2DM (26), and 3) its
genetic inactivation in animals and humans results in
hyperglycemia associated with dysregulation of hepatic
glucose fluxes (27). As expected, Gck mRNA was in-
creased (approximately twofold, P , 0.05 vs. baseline)
after 30-min intraportal insulin delivery in a typical pulsa-
tile pattern (Fig. 6D). In contrast, Gck mRNA did not
increase after insulin delivery in either a constant or
T2DM infusion (Fig. 6D).
Next, we examined whether antecedent intraportal pul-
satile versus constant insulin delivery affects hepatic insulin
signaling in response to an identical subsequent increment
in insulin concentration. This approach thus allowed us to
avoid potential confounding effects of minute-by-minute
insulin concentration changes on hepatic insulin signaling.
This approach revealed that antecedent pulsatile (vs. con-
stant) insulin delivery resulted in increased Gck mRNA and
AKT activation in response to an identical increment in
insulin delivery (Fig. 7).
Finally, we studied the HIP rat model of T2DM to extend
the findings over short periods possible during catheteri-
zation studies (protocols 1–5) to longer periods relevant in
human diabetes. The HIP rat model of T2DM develops a
progressive defect in insulin secretion and b-cell mass as
a result of misfolding and accumulation of toxic oligomers
of human islet amyloid polypeptide developing an islet phe-
notype comparable in many respects with that in humans
with T2DM (6). We now report that defective insulin se-
cretion in the HIP rat mirrors that in humans with T2DM as
a result of a progressive defect in insulin secretory pulse
mass (Fig. 8). Moreover, there was a progressive defect in
hepatic Gck mRNA in the HIP rat that mirrors the pro-
gressive decline in pulsatile insulin secretion and, thus,
lends further support for the importance of pulsatile insulin
secretion in regulation of hepatic Gck gene expression.
DISCUSSION
Impaired fasting glucose and/or impaired glucose tolerance,
often precursors of T2DM, are characterized by b-cell dys-
function and hepatic insulin resistance (4,5,28). Insulin
resistance is also a prominent feature of early T1DM (3) but
is reversed to an extent that b-cell function is restored
in the early treatment phase (3). This raises the question,
does b-cell dysfunction cause hepatic insulin resistance
and thereby set up an adverse positive feedback cycle that
precipitates loss of glycemic control and diabetes onset?
Since insulin is predominately secreted in a pulsatile man-
ner (10,11) and dysregulation of these pulses is an early
defect in T1DM and T2DM (29,30), we tested the hypothesis
that the pulsatile insulin concentration wave front presented
to the liver is important for appropriate insulin signaling
and action.
Prior studies report that pulsatile insulin delivery into
the systemic circulation is more efficacious than constant
insulin infusion (17–19). However, given the volume of
distribution of insulin in the systemic circulation, it is not
possible to reproduce the insulin concentration wave front
presented to hepatocytes in health through this mode of
delivery (10). One study examined delivery of insulin into
the portal vein in pulses or a constant manner during
hyperglycemia (200 mg/dL) and reports no difference in
hepatic glucose uptake (20). However, in that study, in-
sulin was delivered at a rate designed to fully suppress
hepatic glucose release so that no effect of pulsatile in-
sulin delivery on hepatic glucose release was possible,
FIG. 4. AKT and FOXO activation after pulsatile, constant, or T2DM intraportal 10-min insulin delivery protocol in rats. Immunoblot analysis of
biopsied liver samples from rats exposed to 10 min of portal vein insulin delivered in either typical pulsatile fashion, same-rate constant infusion,
or reduced pulses (T2DM). Hepatic biopsies were obtained at 0, 2, 6, and 10 min consecutively from the same liver after the start of portal vein
insulin infusion and immediately preserved using liquid nitrogen. Phosphorylation of AKT and FOXO was determined by immunoblotting with
phosphospecific antibodies against AKT (phospho-Ser473) (A and B) and FOXO (phospho-Ser256) (C and D). Data are mean 6 SE. *P < 0.05 vs.
pulsatile.
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and insulin signaling was not evaluated. Moreover the in-
sulin pulse frequency delivered in those studies (12-min
pulse interval) differed from that used here (6-min pulse
interval), the latter reflecting the insulin pulse frequency
established in vivo using validated methods for pulse de-
tection measured directly in the portal vein (10,31).
The findings of the current study support the hypothesis
that the pulsatile mode of insulin secretion delivered into
the portal vein is more efficacious than a comparable rate
of constant intraportal vein insulin delivery. Furthermore,
intraportal infusion of the T2DM pattern of insulin pulses
in the same dogs resulted in a blood glucose concentration
profile classified diabetes (Fig. 1), despite insulin concen-
trations in the systemic circulation comparable with the
control insulin infusion.
In the current study, having established that intraportal
delivery of insulin in physiological insulin pulses is impor-
tant for insulin action, we then examined the mechanism
subserving this by studying activation of insulin signaling
pathways in the rat liver exposed to the same three patterns
of insulin delivery. Activation of both the IRS-1 and IRS-2
limbs of the insulin signaling pathways was delayed and
attenuated with either the constant or T2DM pattern of
insulin pulses compared with control pulses. Moreover,
the impaired activation of Foxo1 by the constant or T2DM
pattern of insulin delivery is consistent with the impaired
insulin action by those modes of insulin delivery (32,33).
Also, given the important role of Foxo1 in regulation of
hepatic lipid metabolism (34,35), the association between
insulin resistance and increased risk of cardiovascular
disease in both T1DM and T2DM may be mediated at least
in part by impaired pulsatile insulin delivery to the liver
(36,37).
Impaired insulin-mediated activation of Foxo1, as reported
in response to defective pulsatile insulin delivery here,
would be predicted to lead to impaired expression of Gck
and favor gluconeogenesis over glycolysis with inappro-
priately increased hepatic glucose release and hyperglycemia
(38). This is the pattern of abnormal hepatic glucose
metabolism noted in humans with both T1DM and T2DM
FIG. 5. Intraportal 30-min insulin delivery protocol in rats (rat protocol 4). A: Rats were anesthetized and indwelling catheters were placed into
the mesenteric vein, jugular vein, and carotid artery. B: Rats received a constant infusion of somatostatin (10 mg/kg/min) for 30 min to inhibit
endogenous insulin release. Insulin was infused directly into the portal vein at the rate of 70 pmol/kg/min either in a typical pulsatile pattern, in
a same-rate constant insulin infusion, or as an insulin infusion selected to reproduce that observed in patients with evolving diabetes (;50%
decrease in pulse mass). A variable infusion of 50% dextrose was given intravenously to match systemic plasma glucose concentrations among the
three groups. Sequential hepatic biopsies were obtained at 0 and 30 min after the start of insulin infusion protocols. Plasma glucose (C), free fatty
acid (D), and mean glucose infusion rates (E) required to match plasma glucose levels among the three infusion protocols. Data are mean 6 SE.
*P < 0.05 vs. pulsatile.
A.V. MATVEYENKO AND ASSOCIATES
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(2,39–41). Moreover, the same pattern of defective hepatic
glucose metabolism is present in patients with diabetes due
to mutant Gck (MODY2) (42). It is therefore noteworthy that
we find defective hepatic Gck expression observed with
either the T2DM or constant pattern of insulin delivery
reported here, and, indeed, this is consistent with reported
decreased hepatic Gck activity in the liver of individuals
with T2DM (26). It is of note that in the present studies, the
glucagon concentrations were deliberately comparable in
all three insulin infusion protocols. Since there is relative
hyperglucagonemia in both T1DM and T2DM, the decreased
Gck expression consequent upon abnormal portal vein in-
sulin delivery would potentially be further diminished (43).
We extended the intraportal insulin infusion studies by ex-
amining hepatic gene expression in the HIP rat model of
T2DM. First, we established that the progressive defect of
insulin secretion in this model mirrors that in T2DM in
humans, being characterized by a defect in insulin pulse
mass with no change in pulse frequency (15,16). This defect
in insulin pulse mass was accompanied by impaired mRNA
expression of hepatic Gck, consistent with the short-term
intraportal vein insulin infusion studies reported here as
well as defective hepatic Gck expression in humans with
T2DM (26).
Hepatic insulin clearance decreases if intraportal vein
insulin secretion declines because of decreased insulin
secretory burst mass and pulse amplitude (13,44,45), likely
explaining the decreased hepatic insulin clearance of en-
dogenously secreted insulin in T2DM (46). Hepatic insulin
clearance is an insulin receptor–mediated process, and after
the insulin receptor and insulin ligand interact, the receptor
internalizes as downstream signaling is effected before the
receptor is returned to the cell surface ;4 min later (47,48).
The timing of the insulin receptor to complete this itinerary
thus is perfectly suited to entrain to the episodic delivery
of insulin via the sinusoids directly to hepatocytes (48).
FIG. 6. AKT, FOXO, and Gck mRNA activation after pulsatile, constant, or T2DM intraportal 30-min insulin delivery protocol in rats. Immunoblot
analysis of liver samples from rats exposed to 30 min of portal vein insulin delivery in either typical pulsatile fashion, same-rate constant infusion,
or reduced pulses (T2DM). Hepatic biopsies were obtained at 0 and 30 min after the start of insulin infusion and immediately preserved using
liquid nitrogen. Phosphorylation of AKT and FOXO was determined by immunoblotting with phosphospecific antibodies against AKT (phospho-
Ser473) (A) and FOXO (phospho-Ser256) (B). C: FOXO nuclei exclusion after insulin delivery was examined by immunofluorescent staining for
FOXO (red), perivenous hepatocyte marker glutamine synthetase (GS) (green), and nuclear marker DAPI (blue). D: Gck mRNA expression was
determined by real-time PCR in liver samples from rats exposed to 30 min of portal vein insulin delivered in either typical pulsatile fashion, same-
rate constant infusion, or reduced pulses (T2DM). Data are mean 6 SE. *P < 0.05 vs. pulsatile, **P < 0.05 vs. min-0. (A high-quality digital
representation of this figure is available in the online issue.)
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Moreover, the optimal insulin insulin-receptor binding af-
finity occurs at a concentration reproduced by the insulin
concentration wave front delivered by the insulin pulses
(48,49). In addition, intermittent insulin delivery may
permit more efficient transmission of insulin signaling by
avoiding negative feedback. Thus, the action of down-
stream insulin signaling targets to inhibit proximal insulin
signaling effecter molecules might decay before the arrival
of the next signal (50).
Circulating free fatty acids have also been reported to
influence the actions of insulin in regulating hepatic glucose
release (51). In the present studies, we did not observe any
differences in circulating free fatty acids with the three
intraportal insulin infusion protocols, presumably be-
cause systemic insulin concentrations were comparable
(21). The beneficial actions of pulsatile insulin delivery on
hepatic insulin signaling reported here therefore do not
appear to be mediated by changes in free fatty acid
concentrations.
In conclusion, hepatic insulin signaling is delayed and
impaired when insulin is delivered in a nonpulsatile
manner or that which reproduces defective insulin se-
cretion in T2DM. The relatively early development of
hepatic insulin resistance in T1DM and T2DM may thus
in part be a consequence of b-cell dysfunction and loss
of the optimal pattern of pulsatile insulin delivery. The
FIG. 7. Effects of antecedent pulsatile vs. constant insulin delivery on hepatic insulin signaling and gene expression in rats (rat protocol 5). A:
Antecedent portal vein insulin infusion protocol. In short, all rats had a mesenteric and jugular vein infusion catheter and carotid artery
sampling catheter placed surgically under anesthesia; after 6-day recovery, two random cohorts of rats (n = 4 per group) underwent a 150-min
study protocol. During somatostatin inhibition of endogenous insulin secretion, one cohort of rats (pulsatile) received 120-min insulin in-
fusion into the mesenteric vein at a basal physiological rate (7 pmol/kg/min) in 5-min pulses to recapitulate fasting insulin secretion. Another
cohort of rats (constant) received the same rate (7 pmol/kg/min) 120-min insulin infusion into the mesenteric vein, but as a constant infusion.
After 120-min portal vein antecedent insulin infusion, all rats received an identical 30-min bolus of insulin (70 pmol/kg/min) designed to
recapitulate the postprandial rise in insulin secretion. After the 30-min bolus insulin infusion, all rats were euthanized and livers quickly
removed for subsequent analysis of protein and gene expression. Dextrose (50%) was infused at variable rates throughout the 150-min study
protocol to clamp plasma glucose concentrations at basal levels. B: Hepatic portal vein insulin infusion rates in rats receiving 120-min
pulsatile vs. constant antecedent insulin delivery. Plasma glucose levels (C) and mean glucose infusion rates (D) during the 150-min study
protocol in rats receiving 120-min antecedent pulsatile or constant insulin delivery into the hepatic portal vein. E and F: Immunoblot analysis
of liver samples from rats exposed to either antecedent pulsatile or constant portal vein insulin delivery. Hepatic biopsies were obtained at the
end of the 150-min study protocol and immediately preserved using liquid nitrogen. Phosphorylation of AKT was determined by immunoblotting with
phosphospecific antibodies against AKT (phospho-Ser473). G: Gck mRNA expression was determined by real-time PCR. Data are mean 6 SE.
*P < 0.05 vs. pulsatile. (A high-quality color representation of this figure is available in the online issue.)
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resulting increased b-cell workload on failing b-cells in
evolving T1DM or T2DM likely hastens b-cell failure,
collectively leading to diabetes onset.
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